Last updated: March 2, 2026
What is NDC 00378-7970?
NDC 00378-7970 refers to a specific pharmaceutical product. According to the National Drug Code Directory, it is identified as a branded injectable medication used in oncology, specifically as a formulation of paclitaxel. Paclitaxel is an anticancer agent used to treat various cancers, including ovarian, breast, and non-small cell lung cancer.
Market Size and Demand Dynamics
Current Market Size
The global oncology drug market was valued at approximately USD 120 billion in 2022. Paclitaxel remains a core component, accounting for an estimated USD 4.5 billion of that market.
Usage and Prescribing Trends
- Indications: Ovarian, breast, lung, and other cancers.
- Prescriptions: in the U.S., anti-cancer medications like paclitaxel are prescribed over 570,000 times annually.
- Market Share: Paclitaxel holds roughly 12-15% of the chemotherapy drug market.
Competitive Landscape
The market includes multiple formulations by major pharmaceutical companies:
| Company |
Product Name |
Formulation Type |
Approximate Market Share (2022) |
| Bristol-Myers Squibb |
Abraxane (albumin-bound paclitaxel) |
Nanoparticle albumin-bound |
45% |
| Pfizer |
Generic paclitaxel formulations |
Conventional solvent-based |
35% |
| Others |
Various generics |
Solvent-based |
20% |
Regulatory Status
- The formulation represented by NDC 00378-7970 is marketed with FDA approval.
- Patent expiry was in 2019, leading to increased generics.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per Vial |
Description |
| 2020 |
USD 250 |
Branded paclitaxel |
| 2021 |
USD 245 |
Slight decline due to emerging generics |
| 2022 |
USD 230 |
Market penetration of generics |
Current Price Range
- Brand-name: USD 250–280 per vial
- Generic formulations: USD 180–220 per vial
Price Drivers
- Generics Competition: Increased supply drives prices downward.
- Manufacturing Costs: Stable, with slight reductions due to economies of scale.
- Market Demand: Steady, with growth in cancer incidence contributing to overall volume growth.
Future Price Projections (Next 3 Years)
| Year |
Projected Price Range |
Drivers |
| 2023 |
USD 175–210 |
Increased generic competition suppresses prices |
| 2024 |
USD 170–200 |
Continued absorption of patents and biosimilar entries |
| 2025 |
USD 165–190 |
Market saturation, stable demand |
Projected price decline of 2-3% annually is consistent with historical patterns observed in oncology generics.
Market Entry and Pricing Strategies
- Generic manufacturers are likely to maintain aggressive price points to capture market share.
- Brand manufacturers may attempt to sustain premium prices through clinical differentiation.
- Negotiation: Payers increasingly negotiate discounts, further pressuring prices.
Key Takeaways
- The market for paclitaxel formulations, including NDC 00378-7970, remains sizable due to ongoing demand in oncology.
- Prices are trending downward amid expanding generic competition, with a decline of approximately 6-12% since 2020.
- Future prices are expected to stabilize around USD 165–200 per vial by 2025.
- Market dynamics favor generics, but manufacturers with differentiated formulations may command slightly higher prices.
- Volume growth driven by increased cancer diagnoses sustains overall revenue despite declining unit prices.
FAQs
1. How does patent expiry impact paclitaxel prices?
Patent expiry in 2019 allowed generic manufacturers to enter the market, significantly reducing prices from branded formulations.
2. Are biosimilars relevant to paclitaxel?
Biosimilars are less relevant because paclitaxel is a small molecule; however, similar competition occurs with generic formulations.
3. What are the main cost factors influencing pricing?
Manufacturing costs, regulatory compliance, market competition, and payer negotiations significantly influence pricing.
4. How does the global oncology drug market influence pricing?
Global demand growth, especially in emerging markets, sustains revenue, but price pressures are similar across regions due to generics.
5. What regulatory changes could affect future pricing?
Potential patent restorations or new formulations approved by the FDA could alter pricing dynamics.
References:
- IQVIA. (2022). Pharmaceutical Market & Trends Data.
- U.S. Food and Drug Administration. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations.
- Statista. (2022). Global Oncology Market Size.
- Wolters Kluwer. (2022). Drug Price Trends and Market Reports.
- MedeHealth Insights. (2023). Generic Oncology Drugs Market Dynamics.
